VOYAGER THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: VOYAGER THERAPEUTICS INC. - COMMON STOCK

25 Sep 2024 06:47:24 By NetDania Notify

Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected

16 Sep 2024 04:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: VOYAGER THERAPEUTICS INC. - COMMON STOCK

06 Sep 2024 09:01:22 By NetDania Notify

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

05 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Aug 2024 13:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

29 Aug 2024 04:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

07 Aug 2024 04:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

06 Aug 2024 13:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

30 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Jul 2024 13:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Jul 2024 13:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

13 Jun 2024 13:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

13 Jun 2024 04:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

16 May 2024 04:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

13 May 2024 13:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

08 May 2024 03:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

06 May 2024 04:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

22 Apr 2024 13:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

16 Apr 2024 04:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 Mar 2024 13:01:00 By Nasdaq GlobeNewswire